Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2021-08-10 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - PRELIMINARY RESULT OF TELITACICEPT IN THE PHASE II STUDY TO TREAT IgA NEPHROPATHY (IgAN) IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by RemeGen Co., Ltd. regarding preliminary clinical study results of a drug (telitacicept) for treating IgA nephropathy. It contains no financial data, no regulatory form references, no voting results, no management changes, no earnings or annual report content. The document is relatively short (4311 characters) and serves as an announcement of clinical trial results rather than a financial or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is a voluntary announcement about clinical study progress, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-08-10 English
INSIDE INFORMATION - ENTERING INTO THE LICENSE AGREEMENT WITH SEAGEN
Regulatory Filings Classification · 95% confidence The document is an announcement by RemeGen Co., Ltd. regarding entering into a license agreement with Seagen. It is labeled as an "Inside Information" announcement pursuant to the Listing Rules of the Hong Kong Stock Exchange. The content focuses on the terms of the license agreement, payments, and strategic implications. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is about a significant corporate transaction (license agreement) but does not describe a merger or acquisition filing or tender offer. It is not a report or presentation but a regulatory announcement of a material contract. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories such as M&A, Capital Updates, or Earnings Releases.
2021-08-09 English
Monthly Return of Equity Issuer on Movement in Securities for the month ended 31 July 2021
Regulatory Filings Classification · 95% confidence The document is a monthly return report detailing movements in securities, specifically authorized and issued shares, for Overseas Chinese Town (Asia) Holdings Limited. It includes confirmations related to share capital and securities issuance under the Exchange Listing Rules of the Hong Kong Stock Exchange. The document is structured as a regulatory submission with no financial statements or management discussion. It is not an annual or interim report, earnings release, or any form of presentation. It is a regulatory filing reporting share capital movements and confirmations required by the exchange. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length (6225 characters) and content confirm it is a substantive regulatory report rather than a brief announcement or certification only.
2021-08-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2021
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report on movements in securities, specifically focusing on authorized/registered share capital and issued shares for the month ended 31 July 2021. It includes confirmations related to share issuance and compliance with listing rules on the Hong Kong Stock Exchange. The document does not contain financial statements or earnings data but rather regulatory compliance information about share capital and share movements. It is a regulatory announcement related to share capital and securities movements, fitting the category of Regulatory Filings (RNS) as it does not fit into more specific categories like Share Issue/Capital Change (SHA) or Transaction in Own Shares (POS) because there are no changes reported (all increases/decreases are zero). The document is also not a report publication announcement or certification letter but a formal regulatory filing of share capital status and confirmations.
2021-08-04 English
VOLUNTARY ANNOUNCEMENT - REMEGEN RECEIVED ETHICS APPROVAL FOR THE PHASE I TRIAL OF THE ANTIBODY DRUG CONJUGATE (ADC) RC118 IN AUSTRALIA, AND WILL INITIATE THE STUDY TO TREAT CLAUDIN18.2 POSITIVE PATIE
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by RemeGen Co., Ltd. regarding receiving ethics approval for a Phase I clinical trial of a new antibody drug conjugate (ADC) product. It discusses the initiation of a clinical study and provides background on the product and regulatory filings. The document is relatively short (3558 characters) and does not contain financial data, financial statements, or detailed financial analysis. It is an announcement about a clinical trial approval and study initiation, not a financial report or regulatory filing related to financial performance or governance. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a regulatory filing in the sense of compliance or officer certifications. The content is a voluntary announcement about a clinical trial approval, which is best categorized under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-07-30 English
VERY SUBSTANTIAL ACQUISITION ACQUISITION OF LAND USE RIGHTS IN HEFEI AIRPORT INTERNATIONAL TOWN
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a circular issued by Overseas Chinese Town (Asia) Holdings Limited dated 26 July 2021. It discusses a very substantial acquisition of land use rights in Hefei Airport International Town, including detailed definitions, background, consideration, and contractual terms. The document is addressed to shareholders and provides comprehensive information about the acquisition, including financial information of the group and legal agreements. The presence of detailed financial and transactional information, the formal structure, and the fact that it is a circular to shareholders about a major acquisition indicate that this is a Proxy Solicitation & Information Statement (PSI) or a circular related to a significant transaction requiring shareholder approval. It is not a simple announcement or a brief regulatory filing, nor is it a full annual or interim report. It is not a merger proxy statement but a circular related to a very substantial acquisition requiring shareholder information and possibly approval. Therefore, the best fitting category is Proxy Solicitation & Information Statement (PSI).
2021-07-23 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.